Cargando…

Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time

OBJECTIVE: As a member of interleukin-12 family, interleukin-35 (IL-35) plays an important regulatory role in immune response. The relationship between IL-35 and idiopathic membranous nephropathy (IMN) is still unclear, and the purpose of this study is to clarify the relationship between IL-35 and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Na, Dai, Haoran, Dong, Xuan, Liu, Wenbin, Jiang, Hanxue, Zhao, Qihan, Gao, Yu, Feng, Zhendong, Dong, Zhaocheng, Hu, Yuehong, Huang, Guangrui, Rui, Hongliang, Liu, Baoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379805/
https://www.ncbi.nlm.nih.gov/pubmed/35983038
http://dx.doi.org/10.3389/fimmu.2022.926368
_version_ 1784768752692232192
author Zhang, Na
Dai, Haoran
Dong, Xuan
Liu, Wenbin
Jiang, Hanxue
Zhao, Qihan
Gao, Yu
Feng, Zhendong
Dong, Zhaocheng
Hu, Yuehong
Huang, Guangrui
Rui, Hongliang
Liu, Baoli
author_facet Zhang, Na
Dai, Haoran
Dong, Xuan
Liu, Wenbin
Jiang, Hanxue
Zhao, Qihan
Gao, Yu
Feng, Zhendong
Dong, Zhaocheng
Hu, Yuehong
Huang, Guangrui
Rui, Hongliang
Liu, Baoli
author_sort Zhang, Na
collection PubMed
description OBJECTIVE: As a member of interleukin-12 family, interleukin-35 (IL-35) plays an important regulatory role in immune response. The relationship between IL-35 and idiopathic membranous nephropathy (IMN) is still unclear, and the purpose of this study is to clarify the relationship between IL-35 and disease activity and remission of IMN. METHODS: This study was a single-center, retrospective study in which all patients were diagnosed with IMN by renal biopsy or aPLA2R titer and treated with Mahuang Fuzi and Shenzhuo Decoction (MFSD). A follow-up was conducted with the endpoint of clinical complete or partial remission (CR+PR). Levels of serum IL-35 were measured and its relationship with IMN remission were analyzed. The regulatory T cell (Treg) and inducible IL-35 producing Tregs (iTR35) in peripheral blood of IMN patients were detected by flow cytometry. RESULTS: A total of 76 IMN patients (age 51.95 ± 13.29) were followed-up for 18 (12, 24) months. The level of serum IL-35 in all patients increased after treatment, but the degree of increase in remission group was significantly higher than that in no remission (NR) group (117.6% vs 83.7%, P<0.01). The baseline IL-35 level in remission group was higher than that in NR group (174.87 vs.151.87 pg/ml, P=0.016). Cox regression analysis showed that baseline IL-35 level was a independent risk factor for IMN remission (HR 1.081, 95%CI 1.048-1.116, P<0.001). Patients with baseline IL-35 lower than the lower quartile (≤145.49 pg/ml) had an average remission time twice as long as those with baseline IL-35 higher than the upper quartile (> 203.05 pg/ml) (12mon vs. 24mon, P<0.01). The baseline IL-35 can predict the remission time of IMN patients with either aPLA2R positive (AUC=0.673) or negative (AUC=0.745). Analysis of 18 patients with IMN showed that IL-35 level had a higher correlation with iTR35, but not Treg (r=0.613, P<0.05). CONCLUSIONS: The level of IL-35 in patients with IMN showed an increasing trend with the progress of treatment, and the baseline IL-35 could predict the remission time of IMN patients, including those patients with negative aPLA2R. The level of IL-35 is related to the number of iTR35 cells.
format Online
Article
Text
id pubmed-9379805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93798052022-08-17 Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time Zhang, Na Dai, Haoran Dong, Xuan Liu, Wenbin Jiang, Hanxue Zhao, Qihan Gao, Yu Feng, Zhendong Dong, Zhaocheng Hu, Yuehong Huang, Guangrui Rui, Hongliang Liu, Baoli Front Immunol Immunology OBJECTIVE: As a member of interleukin-12 family, interleukin-35 (IL-35) plays an important regulatory role in immune response. The relationship between IL-35 and idiopathic membranous nephropathy (IMN) is still unclear, and the purpose of this study is to clarify the relationship between IL-35 and disease activity and remission of IMN. METHODS: This study was a single-center, retrospective study in which all patients were diagnosed with IMN by renal biopsy or aPLA2R titer and treated with Mahuang Fuzi and Shenzhuo Decoction (MFSD). A follow-up was conducted with the endpoint of clinical complete or partial remission (CR+PR). Levels of serum IL-35 were measured and its relationship with IMN remission were analyzed. The regulatory T cell (Treg) and inducible IL-35 producing Tregs (iTR35) in peripheral blood of IMN patients were detected by flow cytometry. RESULTS: A total of 76 IMN patients (age 51.95 ± 13.29) were followed-up for 18 (12, 24) months. The level of serum IL-35 in all patients increased after treatment, but the degree of increase in remission group was significantly higher than that in no remission (NR) group (117.6% vs 83.7%, P<0.01). The baseline IL-35 level in remission group was higher than that in NR group (174.87 vs.151.87 pg/ml, P=0.016). Cox regression analysis showed that baseline IL-35 level was a independent risk factor for IMN remission (HR 1.081, 95%CI 1.048-1.116, P<0.001). Patients with baseline IL-35 lower than the lower quartile (≤145.49 pg/ml) had an average remission time twice as long as those with baseline IL-35 higher than the upper quartile (> 203.05 pg/ml) (12mon vs. 24mon, P<0.01). The baseline IL-35 can predict the remission time of IMN patients with either aPLA2R positive (AUC=0.673) or negative (AUC=0.745). Analysis of 18 patients with IMN showed that IL-35 level had a higher correlation with iTR35, but not Treg (r=0.613, P<0.05). CONCLUSIONS: The level of IL-35 in patients with IMN showed an increasing trend with the progress of treatment, and the baseline IL-35 could predict the remission time of IMN patients, including those patients with negative aPLA2R. The level of IL-35 is related to the number of iTR35 cells. Frontiers Media S.A. 2022-08-02 /pmc/articles/PMC9379805/ /pubmed/35983038 http://dx.doi.org/10.3389/fimmu.2022.926368 Text en Copyright © 2022 Zhang, Dai, Dong, Liu, Jiang, Zhao, Gao, Feng, Dong, Hu, Huang, Rui and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Na
Dai, Haoran
Dong, Xuan
Liu, Wenbin
Jiang, Hanxue
Zhao, Qihan
Gao, Yu
Feng, Zhendong
Dong, Zhaocheng
Hu, Yuehong
Huang, Guangrui
Rui, Hongliang
Liu, Baoli
Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title_full Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title_fullStr Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title_full_unstemmed Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title_short Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
title_sort level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379805/
https://www.ncbi.nlm.nih.gov/pubmed/35983038
http://dx.doi.org/10.3389/fimmu.2022.926368
work_keys_str_mv AT zhangna levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT daihaoran levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT dongxuan levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT liuwenbin levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT jianghanxue levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT zhaoqihan levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT gaoyu levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT fengzhendong levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT dongzhaocheng levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT huyuehong levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT huangguangrui levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT ruihongliang levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime
AT liubaoli levelofinterleukin35inpatientswithidiopathicmembranousnephropathyanditspredictivevalueforremissiontime